Enoblituzumab

Enoblituzumab
Monoclonal antibody
Type ?
Source Humanized (from mouse)
Target B7-H3
Clinical data
ATC code none
Identifiers
CAS Number 1353485-38-7
ChemSpider none
Chemical and physical data
Formula C6474H9990N1726O2030S42
Molar mass 145.8 kg/mol

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug was developed by MacroGenics, Inc.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.